Overall, this phase 1b trial demonstrates that combined cagrilintide and semaglutide therapy is safe, well-tolerated, and offers clinically meaningful weight loss compared to placebo, warranting further investigation for weight management in obesity
Database 2024:113
Sikiri, P., Mazul, B., Seiwerth, S., Grabarevi, Z., Rucman, R., Petek, M., Jagi, V., Turkovi, B., Rotkvi, I., Mise, S., Zorici, I., Jurina, L., Konjevoda, P., Hanzevacki, M., Gjurasin, M., Separovi, J., Ljubanovi, D., Artukovi, B., Bratuli, M., Tisljar, M., Sumajstorci, J
For ANDA submissions, Population Bioequivalence (PBE) analysis is required on the SAC data to demonstrate that the generic products dose delivery is statistically equivalent to the reference listed drug (RLD)
The procedure itself will take just a couple of minutes